{
    "clinical_study": {
        "@rank": "25118", 
        "arm_group": [
            {
                "arm_group_label": "Serelaxin", 
                "arm_group_type": "Experimental", 
                "description": "Serelaxin will be administered at a dose of 30 \u03bcg/kg/24h by intravenous infusion for 48 hours"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo will be administered by intravenous infusion for 48 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a mechanistic study in patients with coronary artery disease on the effects of\n      Serelaxin on micro- and macrovascular  function."
        }, 
        "brief_title": "Study of the Vascular Effects of Serelaxin", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients \u226518 years of age, with body weight <160 kg.\n\n          -  Patients with proven obstructive coronary artery disease, determined either by\n             functional (e.g. treadmill testing) or non-invasive clinical imaging assessments\n             (e.g. stress-echo, PET or SPECT myocardial perfusion), or invasive coronary\n             angiography or by CT coronary angiography at any point in time in patients with or\n             without mild left ventricular systolic dysfunction (LVSD)\n\n        Exclusion Criteria:\n\n          -  Previous treatment with serelaxin (also known as: RLX030, relaxin)\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, unless they are using highly effective methods of contraception\n             during dosing of study treatment.\n\n          -  Current or planned dialysis.\n\n          -  Impaired renal function during screening defined as an estimated glomerular\n             filtration rate (eGFR) at screening and prior to treatment of <30 mL/min/1.73 m2,\n             calculated using the simplified Modification of Diet in Renal Disease (sMDRD)\n             equation due to potential issue with administration of GdDTPA used as the MRI\n             contrast agent.\n\n          -  Sick-Sinus-Syndrome\n\n          -  Current or history of pulmonary edema, including suspected sepsis.\n\n          -  restrictive, or constrictive cardiomyopathy (does not include restrictive mitral\n             filling patterns seen on Doppler echocardiographic assessments of diastolic function)\n\n          -  Known significant valvular disease (including any of the following: severe aortic\n             stenosis [AVA < 1.0 or peak gradient > 50 on prior or current echocardiogram], severe\n             aortic regurgitation, or severe mitral stenosis).\n\n          -  Clinical diagnosis of acute coronary syndrome (ACS) including unstable angina within\n             30 days prior to screening as determined by both clinical and enzymatic criteria\n\n          -  Troponin elevation and dynamics indicative of ACS at any time between screening and\n             randomization.\n\n          -  Previous myocardial infarction within 3 months of screening\n\n          -  History of Coronary Artery Bypass Graft (CABG) surgery\n\n          -  Heart failure due to significant arrhythmias (including any of the following:\n             ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 beats per minute\n             or any second or third degree AV block or atrial fibrillation/flutter with\n             ventricular response of > 120 beats per minute)\n\n          -  Any surgical or medical condition which in the opinion of the investigator may place\n             the patient at higher risk from his/her participation in the study (e.g., history of\n             poor tolerance of adenosine or 3 vessel coronary disease)\n\n          -  Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive\n             cardiomyopathy (does not include restrictive mitral filling patterns seen on Doppler\n             echocardiographic assessments of diastolic function).\n\n        Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01979614", 
            "org_study_id": "CRLX030A2203", 
            "secondary_id": "2012-001945-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Serelaxin", 
                "description": "Serelaxin solution diluted in 5% glucose volume/volume  (v/v) solution", 
                "intervention_name": "Serelaxin", 
                "intervention_type": "Drug", 
                "other_name": "RLX030, relaxin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "5% v/v glucose solution", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "coronary artery disease", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clydebank", 
                        "country": "United Kingdom", 
                        "state": "West Dumbartonshire", 
                        "zip": "G81 4HX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom", 
                        "zip": "LE3 9QP"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Myocardial perfusion and coronary flow will be evaluated by adenosine-stress cardiac MRI at pre-dose on Day 1 and at 47 hours after the start of the 48h drug infusion", 
                "measure": "Change from baseline in micro-vascular function assessed by regional and global determinations of myocardial perfusion", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose on Day 1 (baseline) and prior to the end of the 48 hour drug infusion"
            }, 
            {
                "description": "Augmentation index will be assessed using the SphygmoCor device at pre-dose on Day 1 and at 2, 6, 24, and 47 hours after the start of the 48h drug infusion", 
                "measure": "Change from baseline in macro-vascular function assessed by augmentation index (AIx)", 
                "safety_issue": "No", 
                "time_frame": "From pre-dose on Day 1 (baseline) until prior to the end of the 48h drug infusion"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01979614"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Aortic distensibility will be assessed by MRI and pulse wave velocity using the SphygmoCor device", 
                "measure": "Change from baseline in aortic distensibility", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose on Day 1 (baseline) until Day 180 after the start of drug infusion"
            }, 
            {
                "description": "Augmentation index will be assessed using the SphygmoCor device at 50h, 54h, Day 30 and at Day 180 after the start of the drug infusion in addition to the timepoints specified under the primary outcome measures", 
                "measure": "Change from baseline in augmentation index", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose on Day 1 (baseline) until Day 180 after the start of drug infusion"
            }, 
            {
                "description": "Pulse wave velocity will be assessed by the SphygmoCor device at pre-dose on Day1, and at 24, 47h, Day 30, and Day 180 after the start of drug infusion", 
                "measure": "Change from baseline in pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose on Day1 (baseline) until Day 180 after the start of drug infusion"
            }, 
            {
                "description": "Monitoring of adverse events, serious adverse events, and death from screening until the end of the study", 
                "measure": "Number of participants with adverse events, serious adverse events, and death", 
                "safety_issue": "Yes", 
                "time_frame": "From the screening visit until Day 180"
            }, 
            {
                "description": "Blood samples will be taken to measure serelaxin concentration at Pre-dose on Day 1, and at 24h, 48h, 50h, 54h, and Day 30 after the start of the 48h drug infusion. The steady state concentration will be estimated using the serum concentration at the 48h timepoint.", 
                "measure": "Serum concentration of serelaxin", 
                "safety_issue": "No", 
                "time_frame": "From pre-dose on Day 1 until Day 30 after the start of drug infusion"
            }, 
            {
                "description": "Blood samples will be taken to measure antibodies to serelaxin concentration at Pre-dose on Day 1, and at Day 30 after the start of the 48h drug infusion", 
                "measure": "Serum concentration of antibodies to serelaxin", 
                "safety_issue": "No", 
                "time_frame": "From pre-dose on Day 1 until Day 30 after the start of drug infusion"
            }, 
            {
                "description": "Systemic clearance will be estimated using the rate of serelaxin infusion and the steady state concentration.", 
                "measure": "Systemic clearance of serelaxin", 
                "safety_issue": "No", 
                "time_frame": "From pre-dose on Day 1 until 48h after the start of drug infusion"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}